- Additional Proxy Soliciting Materials (definitive) (DEFA14A)
April 22 2009 - 5:30PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 8-K
Current
Report Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 22, 2009
AMYLIN PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or Other
Jurisdiction of
Incorporation)
|
|
0-19700
(Commission File
Number)
|
|
33-0266089
(I.R.S. Employer
Identification No.)
|
9360 Towne Centre Drive
San Diego, California 92121
(Address of principal executive offices and zip code)
Registrants telephone number, including area
code:
(858)
552-2200
Check the appropriate box below if the Form 8-K is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (
see
General
Instruction A.2. below):
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
x
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CRF 240.13e-4(c))
Item 8.01 Other Events.
On April 22, 2009, Amylin Pharmaceuticals, Inc. issued a media
statement in response to media inquiries.
A copy of the media statement is attached as Exhibit 99.1 and is
incorporated herein by reference.
Item 9.01. Financial Statements
and Exhibits.
(d)
|
Exhibits.
|
|
|
|
|
|
|
|
Number
|
|
Description
|
|
|
|
|
|
99.1
|
|
Media statement
issued by Amylin on April 22, 2009.
|
|
|
|
|
|
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
AMYLIN
PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
|
Dated:
|
April 22,
2009
|
By:
|
/s/ Lloyd A.
Rowland
|
|
|
|
Lloyd A. Rowland
|
|
|
|
Vice
President, Governance and Compliance, and Secretary
|
3
EXHIBIT
INDEX
Number
|
|
Description
|
|
|
|
99.1
|
|
Media statement
issued by Amylin on April 22, 2009.
|
4
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amylin Pharmaceuticals, Inc. (MM) (NASDAQ:AMLN)
Historical Stock Chart
From Sep 2023 to Sep 2024